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A unique case of metaplastic breast carcinoma with an epithelial component showing tumoral necrosis and neuroectodermal
stromal component is described. The tumor grew rapidly and measured 9cm at the time of diagnosis. No lymph node metastases
were present. The disease progressed rapidly and the patient died two years after the diagnosis from a hemorrhage caused by
brain metastases. The morphology and phenotype of the tumor are described in detail and the diﬀerential diagnostic options are
discussed.
1.Introduction
Metaplastic breast carcinoma is a rare tumor and represents
a heterogeneous group of lesions. According to the World
Health Organization (WHO) classiﬁcation, these lesions
are divided into purely epithelial and mixed epithelial—
mesenchymal tumors, with the latter called carcinosarcoma
when the mesenchymal component is malignant [1, 2]. The
mesenchymal component of carcinosarcomas most often
exhibit chondroid, osteoid, or rhabdoid diﬀerentiation, and
neuroid diﬀerentiation of this component is extremely rare.
In this paper, we present a unique case of metaplastic breast
carcinoma with an epithelial component showing tumoral
necrosis and neuroectodermal mesenchymal component.
2. ClinicalHistory
The patient was a 53-year-old Kurdish woman with a large,
rapidly growing mass in her right breast, but who was
otherwise healthy. The patient had no family history of
breast cancer, had given birth to seven children, and was
still menstruating. At the time of presentation, the patient
had a hard 9cm tumor in her right breast that was visible
on inspection. There were no palpable nodes in the axilla.
Mammography showed a multinodular tumor, the largest
nodule being 65mm, with calciﬁcations. Ultrasound con-
ﬁrmed the presence of a well circumscribed nodular tumor
with mixed echogenicity and revealed enlarged pathological
nodes in the axilla. A preoperative core needle biopsy of the
breast lesion showed structures of an obviously malignant
small cell tumor with a high proliferation index, and it was
negative for estrogen and progesterone receptors and HER-
2. preoperative neoadjuvant chemotherapy was given: three
cycles of epirubicin and docetaxel, followed by three cycles
of docetaxel. However, no substantial tumor remission was
observed, and after ﬁve cycles a mastectomy and axillary
lymph node dissection was performed. Because of the poor
response to neoadjuvant chemotherapy, it was decided to
give four cycles of carboplatin and gemzitabin (after a nega-
tive bone scan and computed tomography of the thorax and
abdomen) followed by radiotherapy to the chest wall. Five
months after the termination of radiotherapy dissemination
was diagnosed to the liver, adrenal glands, and lungs. Despite
new chemotherapy, ﬁrst with a ﬂuorouracil, epirubicin, and
cyclophosphamide combination, and thereafter a combina-
tion of carboplatin and paclitaxel together with bevacizumab
therewasarapidprogressandthepatientdiedtwoyearsafter
diagnosis from a haemorrhage caused by brain metastases.2 Pathology Research International
Figure 1: Scanning magniﬁcation of the tumor with the epithelial
component with tumoral necrosis in the centrum. H&E stain.
3.MaterialsandMethods
Histological analysis was performed on formalin-ﬁxed,
paraﬃn-embedded tissue. The immunohistochemical reac-
tions were carried out using Dako autostainer. The following
primary antibodies were used: estrogen receptor (Novocas-
tra, clone 6F11, 1:100), progesterone receptor (Novocastra,
clone 16, 1:100), c-erbB-2 oncoprotein (Dako, HER-2),
mammoglobin (Dako, clone 304-1A5, 1:1), CD56 (Zymed
Laboratories, clone 123C3, 1:100), CD99 (Dako, clone
12E7, 1:100), NSE (Dako, clone BBS/NC/VIH14, 1:500),
synaptophysin (Novocastra, clone 27G12, 1:150), chromo-
granin A (Dako, clone DAK-A3, 1:3000), high molecular
weight cytokeratin (CK; Dako, clone 34BE12, 1:150),
CK8/18 (Novocastra, clone 5D3, 1:50), CK20 (Dako, clone
Ks20.8, 1:100), CK7 (Dako, clone OVTL 12/30, 1:200),
e-cadherin (Dako, clone NCH-38, 1:50), vimentin (Dako,
clone Vim3B4, 1:600), calponin (Dako, clone CALP1,
1:600), p63 (Biocare Medical, clone BC4A4, 1:100), CD10
(Dako, clone 56C6, 1:50), and S-100 protein (Dako, clone
ZO311, 1:3000). EWS-rearrangement for EWS/FLI typ 0.5
and EWS-ERG was tested using real-time PCR analysis.
4.Pathological Features
The tumor appeared as a 90mm, whitish mass upon macro-
scopic examination. The axillary portion of the specimen
contained ten lymph nodes. Microscopically, the tumor
showed solid areas of small cells and large necrotic areas.
In the central part of the tumor, typical “comedo-like”
carcinoma structures (structures with tumoral necrosis)
were found that comprised roughly 10% of the tumor
mass (Figure 1). These duct-like structures were composed
of cohesive medium-size atypical cells and had necrotic
debris in the lumen. No myoepithelium was seen around
thestructures.Thesmall,relativelymonomorphouscellsthat
comprised roughly 90% of the tumor had scanty cytoplasm,
exhibited a focally perivascular distribution, and sometimes
appeared in cell ﬁles, but were most often arranged in large
solid areas (Figure 2). No rosette-like structures were seen.
Importantly, the entire cell population of the mesenchymal
Figure 2: High-power magniﬁcation of the interface area between
the epithelial and the mesenchymal components of the tumor.
Figure 3: Detail from Figure 1 stained for high molecular weight
cytokeratins.
component demonstrated identical morphology; no signs of
chondroid, osteoid, rhabdoid, or other diﬀerentiation were
observed.
The structures with tumoral necrosis exhibited a clear
epithelial phenotype and expressed high molecular weight
and low molecular weight cytokeratins (Figure 3)a n de -
cadherin, and they were negative for vimentin. These
structures weakly and focally expressed CD56. No in situ
component could be demonstrated in the epithelial part of
the tumor using the myoepithelial markers calponin, p63,
and CD10. The solid component of the tumor exhibited
a mesenchymal phenotype: no reaction with cytokeratins
but strong diﬀuse vimentin positivity. The mesenchymal
component of the tumor strongly and diﬀusely expressed the
neuroid markers NSE and CD56 (Figure 4). No positivity
for the estrogen and progesterone receptors, HER-2, mam-
moglobin,calponin,p63,chromograninA,orsynaptophysin
was detected in any part of the tumor. CD10 stained both
components of the tumor focally in about 10% of the section
surﬁces. S-100 protein was present in only the dendritic
cells in the stroma of the tumor. CD99 showed unspe-
ciﬁc focal cytoplasmic reaction in the stromal component.
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Figure 4: Combined image demonstrating the immunophenotype of the mesenchymal component of the tumor showing intensive diﬀuse
CD56 positivity (a), vimentin positivity (c), high Ki-67 index (b), and p53 expression (d).
out negative. The tumor cells in both the epithelial and
mesenchymal portion of the tumor exhibited a very high
percentage of p53-positive cells. The Ki-67 proliferation
index was as high as 90% (Figure 4). No axillary lymph node
metastases were present, but some of the nodes contained
benign nevus structures in their capsule.
Based on the morphology and immunophenotype of
the tumor, the diagnosis of metaplastic carcinoma with a
neuroectodermal stromal component was made.
5. DifferentialDiagnosis
The presence of epithelial and mesenchymal elements in
the same tumor is the hallmark of metaplastic breast
carcinomas with a heterologous component, also named
carcinosarcomas. In our case, the structures with tumoral
necrosis clearly exhibited an epithelial morphology and
immunophenotype, in contrast to the mesenchymal compo-
nent expressing vimentin and the neuronal markers CD56
and NSE. The entire tumor showed signs of malignancy,
suchasrapidgrowth,extremelyhighproliferationindex,and
diﬀuse expression of p53. All of these ﬁndings motivated the
diagnosis of metaplastic carcinoma with a neuroectodermal
mesenchymal component, which represents a real rarity; no
corresponding published case could be found in the English
literature.
Primitive neuroectodermal tumor (PNET) was one of
the main diﬀerential diagnostic alternatives in our case.
Four cases of primary breast PNET has been reported in
the literature [3], but all lacked any epithelial component.
PNET may express keratins in some cases, but the biphasic
(epithelial-mesenchymal) character is not a feature of this
tumor [4]. The stromal component in our case did not
expressCD99anddidnotshowthetypicalmoleculargenetic
patterns which are the hallmarks of PNET.
The case of metaplastic breast carcinoma with neuroglial
diﬀerentiation published by Golshan et al. [5] is similar to
our case, but no glial diﬀerentiation was seen in our tumor.
In addition, the diagnosis in the previous case was seriously
questioned by Hameed and Dehner [6] because the tumor
lacked a typical epithelial component. Milanezi et al. [7]
published a series of breast carcinomas, among them were
ﬁve metaplastic carcinomas, stained for CD99. Four of the
metaplastic tumors expressed CD99, but only one of them
expressed it in the stromal component.
The presence of a heterologous component diﬀerenti-
ated our metaplastic carcinoma from a purely epithelial
neuroendocrine carcinoma of the breast. The cells of these4 Pathology Research International
tumors express epithelial and endocrine markers at the same
time. In the literature, we found a single case of “primary
small cell carcinoma” of the breast that did not express
epithelial markers at all, but expressed CD56 and NSE [8].
This tumor was very similar to the mesenchymal component
of the tumor in our case, but it was not biphasic and
expressed synaptophysin, unlike our case.
The focal distribution of the invasive component indi-
cates the need for thorough sampling of such a large tumor
for proper diagnosis. The relatively monotonous stromal
neuroectodermal component may be misdiagnosed as neu-
roendocrine carcinoma or PNET in absence of thorough
sampling and adequate immunohistochemical support.
Lastly, the metastatic character of the tumor was also
considered as a diﬀerential diagnostic option; however, an
extensive clinical and radiological search did not detect
any additional tumor focus in our patient. The histological
appearance of the typical comedo-like epithelial component
also favored the primary localization of the tumor in the
breast, though an in situ component could not be veriﬁed.
6. Conclusions
The biphasic character of the lesion, obvious signs of
malignancy, and expression of neuroectodermal markers
in the stromal component qualiﬁes the reported case for
being metaplastic carcinoma with neuroectodermal stromal
component. Up to our knowledge, this is the ﬁrst such case
reported in the literature.
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